DOCSLIB.ORG

Curricular Track I—Immunomodulation in Rheumatology and Gastrointestinal Diseases Activity No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curricular Track I—Immunomodulation in Rheumatology and Gastrointestinal Diseases Activity No Curricular Track I—Immunomodulation in Rheumatology and Gastrointestinal Diseases Activity No. 0217-0000-11-105-L01-P (Knowledge-Based Activity) Wednesday, October 19 10:15 a.m.–11:45 a.m. Convention Center: Rooms 304 & 305 Moderator: Eric M. Tichy, Pharm.D., BCPS Clinical Pharmacy Specialist, Solid Organ Transplant, Yale-New Haven Hospital, New Haven, Connecticut Agenda 10:15 a.m. Immunotherapy in Rheumatology: Targeting Inflammation and Disease Progression Lauren K. McCluggage, Pharm.D., BCPS Assistant Professor, Department of Pharmacy Practice, Lipscomb University College of Pharmacy, Nashville, Tennessee 11:00 a.m. Current and Emerging Immunotherapy for Gastrointestinal Diseases Geoffrey C. Wall, Pharm.D., FCCP, BCPS Internal Medicine Clinical Pharmacist, Iowa Methodist Medical Center; Associate Professor of Pharmacy Practice, Drake University College of Pharmacy, Des Moines, Iowa Faculty Conflict of Interest Disclosures Lauren K. McCluggage: no conflicts to disclose. Geoffrey C. Wall: no conflicts to disclose. Learning Objectives 1. Review current trends in management of rheumatoid arthritis. 2. Discuss the role of tumor necrosis factor alpha in rheumatologic disease. 3. Differentiate disease-modifying antirheumatic drug regimens based on the biologic and non- biologic properties. 4. Discuss the unique considerations related to immunotherapy toxicity associated with treatment of rheumatoid arthritis. 5. Discuss the role of immunomodulation for Crohn’s Disease and Ulcerative Colitis. 6. Identify short and long-term complications of immunomodulatory therapy used for gastrointestinal disorders. Self-Assessment Questions Self-assessment questions are available online at www.accp.com/am Annual Meeting Immunotherapy in Rheumatology: Targeting Inflammation and Disease Progress ion Lauren McCluggage, Pharm.D., BCPS Assistant Professor Department of Pharmacy Practice Lipscomb University College of Pharmacy Conflicts of Interest NOTHING TO DISLCOSE. Objectives Review current trends in management of rheumatoid arthritis (RA) Discuss the role of tumor necrosis factor (TNF) alpha in RA Differentiate disease-modifying antirheumatic drug (DMARD) reg imens base d on the bio log ic and non-biologic properties Discuss the u nique considerations related to immunotherapy toxicity associated with treatment of RA RA Treatments Anti-inflammatory Agents NSAIDs Steroids Traditional DMARDs Methotrexate (MTX) , hydroxychloroquine (HCQ), DMARDs sulfasalazine (SSZ), leflunomide (LEF) Other antirheumatic drugs Gold derivatives, cyclosporine, minocycline Biological DMARDs Adalimumab, certolizumab pegol, etanercept, TNF alpha inhibitors golimumab, infliximab IL-1 inhibitors Anakinra Costimulation blocker Abatacept B-cell targe te d therapy Ritux ima b IL-6 receptor antagonist Tocilizumab Pathophysiology TNFα IL-6 IL-1 RF anti-CCP Fibroblasts OC MMP OC=osteoclast MMP=matrix Bone and cartilage erosion , synovitis metalloproteinase Adapted from: http://www.currentclinicalpractice.com/ccp_article.asp?id=5514 and http://pharmacologycorner.com/mechanism-of-action-indications-and-adverse-effects-of-etanercept-infliximab-and- adalimumab/ Disease Evaluation Disease Activity Score (DAS) 28 0-9.4 (<3.2: low disease activity) Tender joints, swollen joints, ESR or CRP, visual analog score American College of Rheumatology (ACR) 70 70% improvement in tender and swollen joints 70% improvement in 3 of 5 Patient pain, patient global assessment, physician global assessment, patient self-assessed disability, acute phase reactants ACR: Duration <6 months Disease Activity Low Moderate High <3 mo 3-6 mo Poor Poor Poor Prognostic Prognostic Prognostic Features Features Features - + -+ - + Cost Limitations + - LEF LEF MTX + SSZ HCQ MTX Anti-TNF MIN SSZ MTX MTX+SSZ+ SSZ MTX+HCQ HCQ +MTX+ MTX Saag KG, et al. Arthritis Rheum. 2008;59:762-84. ACR: Duration >6 months Disease Activity Low Moderate High Poor Prognostic - -/+ + - -/+ + - -/+ + Factors Duration: 6-24 HCQ LEF, MTX+ LEF, SSZ, LEF, months MTX, SSZ+ MTX, SSZ+HCQ MTX, SSZ HCQ SSZ, MTX+HCQ, MTX+HCQ, MTX+SSZ, MTX+ SSZ, MTX+ LEF, MTX+LEF, MTX+SSZ+HCQ MTX+SSZ+HCQ Duration: >24 LEF, MTX+ LEF, MTX+LEF, SSZ LEF months MTX, LEF, MTX, MTX+SSZ+ MTX SSZ, MTX+ SSZ, HCQ MTX+HCQ MTX+HCQ SSZ+ MTX+HCQ MTX+SSZ HCQ MTX+LEF MTX+SSZ+HCQ Failed MTX Anti-TNF monotherapy Failed MTX Non- Abatacept Non- Abatacept combo therapy biologic Anti-TNF biologic Anti-TNF or sequential OR OR Rituximab Anti- DMARDs TNF Anti-TNF Saag KG, et al. Arthritis Rheum. 2008;59:762-84. Treat Aggressively FIN-RACo SSZ + HCQ + MTX + SSZ + prednisolone prednisolone ACR remission – 2 yrs 37% 18% ACR remission – 5 yrs 28% 22% Remission ever – 11 yrs 68% 40% TICORA Monthly monitoring Monitoring every 3 and fixed adjustments months and prn adjustments EULAR remission – 1.5 65% 16% yrs Mottonen T, et al. Lancet. 1999;353:1568-73. Korpela M, et al. Arthritis Rheum. 2004;50:2072-81. Rantalaiho V, et al. Arthritis Rheum. 2009;60:1222-31. Grigor C, et al. Lancet. 2004;364:263-9. Treat Early Anderson JJ, et al. Arthritis & Rheum. 2000;43:22-29. Treat Early Very Early Late Early Treatment Treatment Median disease 3 months 12 months duration Change in DAS28 -2.72 -1.61 P<0.05 DAS28 < 3.2 75% 35% P <0.05 DAS28 < 2.6 50% 15% NR Change in Larsen 3.6 14.7 P<0.05 scores ACR70 response 55% 20% PP0.05<0.05 Nell VPK, et al. Rheumatology. 2004;43:906-14. 2010 ACR Classification JOINT DISTRIBUTION (0‐5) > 1 joint with 1 large joint 0 definite synovitis 2‐10 large joints 1 1‐3 small joints (large joints not counted) 2 Synovitis not 4‐10 small joints (large joints not counted) 3 >10 joints ( at least one small j)joint) 5 better explained SEROLOGY (0‐3) Negative RF AND negative ACPA 0 by another Low positive RF OR low positive ACPA 2 disease High positive RF OR high positive ACPA 3 SYMPTOM DURATION (0‐1) <6 weeks 0 ≥6 wee ks 1 ACUTE PHASE REACTANTS (0‐1) Normal CRP AND normal ESR 0 >6 = definite RA Abnormal CRP OR abnormal ESR 1 Aletaha D, et al. Arthritis & Rheum. 2010;62:2569-81. Treat to Target: T2T Treatment must be based on decision between patient and rheumatologist Primary goal is to maximize quality of life by controlling symptoms, preventing structural damage and normalizing function and social ppparticipation Suppressing inflammation is the most important way to achieve goals Measuring disease activity and adjusting therapy optimizes outcomes Smolen JS, et al. Ann Rheum Dis. 2010;69:631-637. T2T Assess Assess disease disease activity activity every every 3-6 1-3 months Sustained months Remission remission Adapt Initiate Adapt therapy if Treatment Therapy state is lost Low Sustained Disease low Activity disease activity Smolen JS, et al. Ann Rheum Dis. 2010;69:631-637. Remission T2T Definition Absence of signs and symptoms of significant inflammatory disease activity 2011ACR/EULAR Definition Clinical Trials Clinical Practice Tender joint count (TJC) < 1 TJC < 1 Swollen joint count (SJC) < 1 SWJ < 1 PtGA* < 1 PtGA* < 1 C-reactive protein (CRP) < 1mg/dL Simplifi e d Disease Ac tiv ity IdIndex Clin ica l Disease Ac tiv ity Score (CDAI) (SDAI) score < 3.3 < 2.8 *PtGA: patient global assessment 0-10 scale SDAI = SJC + TJC + PtGA + Provider gg(lobal assessment (PhGA) + CRP CDAI = SJC + TJC + PtGA + PhGA Smolen JS, et al. Ann Rheum Dis. 2010;69:631-637. Felson DT, et al. Arthritis & Rheum. 2011;63:573-86. Anti-TNF α Adalimumab Certolizumab Etanercept Golimumab Infliximab Description Monoclonal Fab’ Dimeric Monoclonal Monoclonal antibody fragment TNF antibody antibody receptor + Fc Fully Yes Yes Yes Yes No humanized RouteSCSCSCSCIV Frequency q2 weeks q2-4 Weekly Monthly Every 8 weeks* weeks* Indication Moderate Moderate Moderate Moderate Moderate to severe to severe to severe to severe to severe with MTX with MTX * Maintenance frequency after induction therapy Other Biologics Abatacept Anakinra Rituximab Tocilizumab Description Costimulation IL-1 receptor Monoclonal Monoclonal modulator antagonist antibody antibody inhibits T-cell against CD20 against IL6 activation antigen Fully Yes Yes No Yes humanized Route IV or SC SC IV IV Frequency q4 weeks or Daily 0 and 2 weeks q4 weeks weekly then every 24 weeks Indication Moderate to Moderate to Moderate to Moderate to severe severe who severe who severe who have failed > have failed >1 have failed >1 1DMARD1 DMARD anti-TNF anti-TNF Biologics in MTX Failure ACR70 Response Rate MTX + p lace bo MTX + bi o log ic 100 90 80 70 60 50 40 30 21 21 20 20 20 15 12 5 8 6 7 10 330 0 22 0 Biologics in Early RA ASPIRE MTX (%) MTX + INF 3mg/kg (%) MTX + INF 6 mg/kg (%) ACR70 21. 2 32. 5* 37. 2* DAS28 <2.6 15 21.2 31.0* > 1 serious infection 2.1 5.6* 5.0* COMET MTX (%) MTX + etanercept (%) DAS28 <2.6 28 50* Non-progression 80 59* Serious infection 3 2 PREMIER MTX (%) MTX + adalimumab (%) Adalimumab (%) DAS28 < 2. 6 25 49** 25 Non-progression 34 61** 45* Serious infections 1.6 2.9^ 0.7 * p<0.05 compared to MTX, **p<0.05 compared to MTX and adalimumab, ^p<0.05 compared to adalimumab St Claire EW, et al. Arthritis Rheum. 2004;50:3432-43. Emery P, et al. Lancet. 2008;372:375-82. Breedveld FC, et al. Arthritis Rheum. 2006;54:26-37. Biologics in Early RA AGREE MTX (%) MTX + abatacept (%) DAS28 < 2. 6 23. 3 41. 4* Non-progression 48.3 59.1* Serious infections 2 2 AMBITION MTX (%) Tocilizumab (%) DAS28 < 2.6 12.1 33.6* Serious infection 0.7 1.4 * p<0.05 compared to MTX Westhovens R, et al. Ann Rheum Dis. 2009;68:1870-77. Jones G, et al. Ann Rheum Dis. 2010;69:88-96. Biologics after TNF Failure Outcome Placebo (%) Biologic (%) Golimumab ACR70 3 12* Abatacept ACR70 1.5 10.2* Rituximab ACR70 1 12* Tocilizumab DAS < 2.6 1.6 4 mg/kg: 1.6 8 mg/kg: 7.6* * p<0.05 compared to placebo Smolen J, et al.
Load more

Recommended publications
  • Immunomodulation: a Broad Perspective for Patients' Survival of COVID-19 Infection
    European Journal ISSN 2449-8955 Review Article of Biological Research DOI: http://dx.doi.org/10.5281/zenodo.3956771 Immunomodulation: a broad perspective for patients’ survival of COVID-19 infection Covenant Femi Adeboboye, Babayemi Olawale Oladejo*, Tinuola Tokunbo Adebolu Department of Microbiology, Federal University of Technology, P.M.B. 704, Akure, Nigeria *Correspondence: Tel: +2349042422526; E-mail: [email protected] Received: 28 May 2020; Revised submission: 15 July 2020; Accepted: 22 July 2020 http://www.journals.tmkarpinski.com/index.php/ejbr Copyright: © The Author(s) 2020. Licensee Joanna Bródka, Poland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/) ABSTRACT: The pathogenesis of the SARS-CoV-2 virus is yet to be well understood. However, patients with the virus show clinical manifestations which are very similar to those of SARS-CoV and MERS-CoV. This and other scientific findings reveal that acute respiratory distress syndrome (ARDS) is the main cause of death in most COVID-19 patients. A vital mechanism for the development of the ARDS is cytokine storm which arises from an aggressive uncontrolled systemic inflammatory response that results from the release of large numbers of pro-inflammatory cytokines. This review seeks to draw the attention of the scientific community to the possibilities of improving the clinical outcome of COVID-19 patients based on the knowledge of altering the development of this hyper-inflammatory process by suggesting drugs that targets the implicated immune cells, receptors, cytokines and inflammatory pathways without having generalized effect on the entire immune system.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0224301 A1 ZAMORA Et Al
    US 20110224301A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0224301 A1 ZAMORA et al. (43) Pub. Date: Sep. 15, 2011 (54) HMGB1 EXPRESSION AND PROTECTIVE Publication Classification ROLE OF SEMAPMOD IN NEC (51) Int. Cl. (75) Inventors: Ruben ZAMORA, Pittsburgh, PA st iOS CR (US); Henri R. FORD, La Canada, (2006.01) CA (US); Thais A6IP3L/2 (2006.01) SIELECK-DZURDZ, Kennett A6IP33/6 (2006.01) Square, PA (US); Vidal F. DE LA CRUZ, Phoenixville, PA (US) (52) U.S. Cl. ........................................................ S14/615 (73) Assignee: CYTOKINE PHARMASCIENCES, INC., King (57) ABSTRACT of Prussia, PA (US) Methods are described, which include the administration of (21) Appl. No.: 12/879,144 semapimod or guanylhydraZone containing compounds, salt thereof, or a combination of the compound and a salt thereof 22) Filed1C Sep.ep. 10,1U, 2010 forOr the 1inhibiti 1t1on, treatment, and/ord/ prevention off any o f NEC, a condition associated with the release of HMGB1, a Related U.S. Application Data condition associated with the release of iNOS protein, a con dition associated with the release of Bax protein, a condition (63) sity pig, S. 21,666 filed on associated with the release of Bad protein, a condition asso • us s • L vs - s -- a-- s- u. I • ciated with the release of COX-2 protein, or a condition (60) Provisional application No. 60/685,875, filed on Jun. associated with the release of RAGE, or a combination 1, 2005. thereof to a subject in need thereof. Patent Application Publication Sep. 15, 2011 Sheet 1 of 12 US 2011/0224301 A1 Fig.
    [Show full text]
  • Semapimod Sensitizes Glioblastoma Tumors to Ionizing Radiation by Targeting Microglia
    Semapimod Sensitizes Glioblastoma Tumors to Ionizing Radiation by Targeting Microglia Ian S. Miller1¤a, Sebastien Didier1, David W. Murray1¤a, Tia H. Turner1, Magimairajan Issaivanan1¤b, Rosamaria Ruggieri1, Yousef Al-Abed2, Marc Symons1* 1 Center for Oncology and Cell Biology, The Feinstein Institute for Medical Research at North Shore-LIJ, Manhasset, New York, United States of America, 2 Center for Molecular Innovation, The Feinstein Institute for Medical Research at North Shore-LIJ, Manhasset, New York, United States of America Abstract Glioblastoma is the most malignant and lethal form of astrocytoma, with patients having a median survival time of approximately 15 months with current therapeutic modalities. It is therefore important to identify novel therapeutics. There is mounting evidence that microglia (specialized brain-resident macrophages) play a significant role in the development and progression of glioblastoma tumors. In this paper we show that microglia, in addition to stimulating glioblastoma cell invasion, also promote glioblastoma cell proliferation and resistance to ionizing radiation in vitro. We found that semapimod, a drug that selectively interferes with the function of macrophages and microglia, potently inhibits microglia- stimulated GL261 invasion, without affecting serum-stimulated glioblastoma cell invasion. Semapimod also inhibits microglia-stimulated resistance of glioblastoma cells to radiation, but has no significant effect on microglia-stimulated glioblastoma cell proliferation. We also found that intracranially administered semapimod strongly increases the survival of GL261 tumor-bearing animals in combination with radiation, but has no significant benefit in the absence of radiation. In conclusion, our observations indicate that semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microglia and/or infiltrating macrophages.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Characterisation of Hmgb1 in Inflammation Characterisation of Hmgb1 in Inflammation
    Thesis for doctoral degree (Ph.D.) 2008 Thesis for doctoral degree (Ph.D.) 2008 CHARACTERISATION OF HMGB1 IN INFLAMMATION CHARACTERISATION OF HMGB1 IN INFLAMMATION CHARACTERISATION Therese Östberg Therese Östberg From the Rheumatology unit, Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden CHARACTERISATION OF HMGB1 IN INFLAMMATION Therese Östberg Stockholm 2008 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Larserics Digital Print AB, Sweden © Therese Östberg, 2008 ISBN 978‐91‐7409‐121‐2 2 To my family 3 The way I see it, if you want the rainbow, you gotta put up with the rain. Dolly Parton 4 SUMMARY High mobility group box chromosomal protein 1 (HMGB1) was discovered over three decades ago as a nuclear protein which is present in all mammalian nucleated cells. Subsequent studies have revealed additional properties of HMGB1 besides its originally described nuclear functions. Extracellular HMGB1 induces cellular migration, recruits stem cells, possesses antibacterial functions and somewhat surprisingly is involved in proinflammatory responses. HMGB1 can be released from certain cells in two distinct ways, either passively by dying cells or through active release from multiple cell types such as myeloid cells. The active secretion of HMGB1 is mediated via a non-classical pathway involving secretory lysosomes, a route sharing many features with the IL-1β secretion pathway. My studies of macrophages from RAGE gene-deficient mice indicate that RAGE is the major functional receptor for HMGB1 on these cells. The results also show that HMGB1 interacts with additional receptor(s), since the absence of RAGE molecules did not completely abolish HMGB1-induced cytokine production.
    [Show full text]
  • New Targets for Mucosal Healing and Therapy in Inflammatory Bowel Diseases
    REVIEW nature publishing group See ARTICLE page 134 New targets for mucosal healing and therapy in inflammatory bowel diseases MF Neurath1 Healing of the inflamed mucosa (mucosal healing) is an emerging new goal for therapy and predicts clinical remission and resection-free survival in inflammatory bowel diseases (IBDs). The era of antitumor necrosis factor (TNF) antibody therapy was a remarkable progress in IBD therapy and anti-TNF agents led to mucosal healing in a subgroup of IBD patients; however, many patients do not respond to anti-TNF treatment highlighting the relevance of finding new targets for therapy of IBD. In particular, current studies are addressing the role of other anticytokine agents including antibodies against interleukin (IL)-6R, IL-13, and IL-12/IL-23 as well as new anti-inflammatory concepts (regulatory T cell therapy, Smad7 antisense, Jak inhibition, Toll-like receptor 9 stimulation, worm eggs). In addition, blockade of T-cell homing via the integrins a4b7 and the addressin mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) emerges as a promising new approach for IBD therapy. Here, new approaches for achieving mucosal healing are discussed as well as their implications for future therapy of IBD. INTRODUCTION IBD was associated with more effective disease control, more Inflammatory bowel diseases (IBD; Crohn’s disease (CD), frequent steroid-free remission of disease, lower rates of ulcerative colitis (UC)) are chronic relapsing diseases that lead to hospitalization and surgery, and improved quality of live as structural damage with destruction of the bowel wall.1–3 compared with conventional treatment goals.12 These findings Clinically, IBD patients can suffer from chronic diarrhea, highlight the role of mucosal healing for therapy of IBD.
    [Show full text]
  • Severe Crohn's Disease Semapimod Induces Clinical Remission in Specific Inhibition of C-Raf Activity By
    Specific Inhibition of c-Raf Activity by Semapimod Induces Clinical Remission in Severe Crohn's Disease This information is current as Mark Löwenberg, Auke Verhaar, Bernt van den Blink, Fibo of September 24, 2021. ten Kate, Sander van Deventer, Maikel Peppelenbosch and Daniel Hommes J Immunol 2005; 175:2293-2300; ; doi: 10.4049/jimmunol.175.4.2293 http://www.jimmunol.org/content/175/4/2293 Downloaded from References This article cites 68 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/175/4/2293.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Specific Inhibition of c-Raf Activity by Semapimod Induces Clinical Remission in Severe Crohn’s Disease1 Mark Lo¨wenberg,2*‡ Auke Verhaar,* Bernt van den Blink,* Fibo ten Kate,† Sander van Deventer,* Maikel Peppelenbosch,§ and Daniel Hommes‡ There is a substantial need for novel treatment strategies in Crohn’s disease (CD), a chronic relapsing inflammatory disease of the gut.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,314,149 B2 Zamora Et Al
    USOO8314149B2 (12) United States Patent (10) Patent No.: US 8,314,149 B2 Zamora et al. (45) Date of Patent: *Nov. 20, 2012 (54) PROTECTIVE ROLE OF SEMAPMOD IN (60) Provisional application No. 60/685,875, filed on Jun. NECROTZNG ENTEROCOLTS 1, 2005. (75) Inventors: Ruben Zamora, Pittsburgh, PA (US); Henri R. Ford, La Canada, CA (US); (51) Int. Cl. Thais Sielecki-Dzurdz, Kennett Square, A613 L/65 (2006.01) PA (US); Vidal F. De La Cruz, A613 L/55 (2006.01) Phoenixville, PA (US) (52) U.S. Cl. ....................................................... S14/615 (58) Field of Classification Search ........................ None (73) Assignees: Feering B.V., Hoofddorp (NL); See application file for complete search history. University of Pittsburgh-Of The Commonwealth System Of Higher (56) References Cited Education, Pittsburgh, PA (US) (*) Notice: Subject to any disclaimer, the term of this PUBLICATIONS patent is extended or adjusted under 35 Caplanet al., Pediatric Pathology, (Nov.-Dec. 1994), 14(6), pp. 1017 U.S.C. 154(b) by 0 days. 1028 (Abstract).* This patent is Subject to a terminal dis claimer. * cited by examiner (21) Appl. No.: 12/879,144 Primary Examiner — Phyllis G. Spivack (74) Attorney, Agent, or Firm — Fish & Richardson P.C. (22) Filed: Sep. 10, 2010 (65) Prior Publication Data (57) ABSTRACT US 2011 FO224301A1 Sep. 15, 2011 A method is disclosed wherein semapimod, and/or the mesy late salt thereof, is administered for the treatment of necro Related U.S. Application Data tizing enterocolitis. (63) Continuation of application No. 1 1/421,666, filed on Jun. 1, 2006, now Pat. No. 7,795,314.
    [Show full text]
  • Gut Inflammation: Current Update On
    Gut inflammation: current update on pathophysiology, molecular mechanism and pharmacological treatment modalities. Gyires K., Tóth V.E., Zádori Z.S. Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4., 1089 Budapest, Hungary Corresponding author: Klára Gyires, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Nagyvárad tér 4., 1089, Budapest, Hungary. Telephone: 36-1-210-4416 FAX: 36-1-210-4412 e-mail: [email protected] Abstract Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory condition of the gastrointestinal tract. The two main forms of IBD are Crohn's disease and ulcerative colitis. According to the recent concept the disease is caused by a combination of factors, including genetics, immune dysregulation, barrier dysfunction and the change in microbial flora. Environmental factors, such as changes in diet, antibiotic use, smoking or improved domestic hygiene (e.g. eradication of intestinal helminths) probably contribute to the development and increased prevalence of IBD. Dysregulation of mucosal immunity in IBD causes an overproduction of inflammatory cytokines resulted in uncontrolled intestinal inflammation. Based on extensive research over the last decade, besides the conventional therapy, there are several novel pathways and specific targets, on which focus new therapeutics. New therapeutics aim 1./ to correct genetic susceptibility by stimulating NOD2 expression, TLR3 signaling or inhibition of TLR4 pathway, 2./ to restore the immune dysregulation by inhibition of pro-inflammatory cytokines (TNF-α, IL-6, IL-13, IL-17, IL-18, IL-21), Th1 polarisation (IL-2, IL-12, IL-23, IFN-γ), T-cell activation, leukocyte adhesion, as well as by immunostimulation (GM-CSF, G-CSF) and anti-inflammatory cytokines (IL-10, IL-11, IFN-β-1a), 3./ to restore mucosal barrier function and stimulate mucosal healing by different growth factors, such as GH, EGF, KGF, TGF-β, VEGF, 4./ to restore the normal bacterial flora by antibiotics, probiotics.
    [Show full text]
  • Blockade of Endogenous Proinflammatory Cytokines Ameliorates Endothelial Dysfunction in Obese Zucker Rats
    737 Hypertens Res Vol.31 (2008) No.4 p.737-743 Original Article Blockade of Endogenous Proinflammatory Cytokines Ameliorates Endothelial Dysfunction in Obese Zucker Rats Hiroaki NISHIMATSU1), Etsu SUZUKI2), Ryo TAKEDA3), Masao TAKAHASHI3), Shigeyoshi OBA3), Kenjiro KIMURA2), Tetsuo NAGANO4), and Yasunobu HIRATA3) To study the role of endogenous proinflammatory cytokines in endothelial dysfunction in diabetes, we administered semapimod, an inhibitor of proinflammatory cytokine production, to obese Zucker (OZ) rats, and examined its effect on endothelium-dependent vasorelaxation. Endothelium-dependent vasorelaxation induced by acetylcholine and adrenomedullin (AM) was significantly reduced in OZ rats compared to a con- trol group of lean Zucker rats. Semapimod significantly restored endothelium-dependent vasorelaxation in OZ rats. This effect of semapimod was well correlated with the reduction in the serum concentrations of tumor necrosis factor-α (TNF-α), interleukin-6, and C-reactive protein, as well as with the recovery of AM- induced Akt phosphorylation and cGMP production. Furthermore, acute administration of TNF-α signifi- cantly suppressed endothelium-dependent vasorelaxation and AM-induced cGMP production. These results implicate endogenous proinflammatory cytokines, especially TNF-α, in endothelial dysfunction in diabetes, and indicate that blockade of these cytokines will be a promising strategy for inhibiting the progression of vascular inflammation. (Hypertens Res 2008; 31: 737–743) Key Words: diabetes, endothelial dysfunction, proinflammatory cytokines, adrenomedullin nisms of endothelial dysfunction remain unclear, reactive Introduction oxygen species (ROS) seem to play a role in that process (4–7). Diabetes mellitus is now well known as a major risk factor for Several lines of evidence suggest that insulin resistance cardiovascular diseases (1, 2).
    [Show full text]
  • An Inter-Species Translation Model Implicates Integrin Signaling in Infliximab-Resistant Colonic Crohn’S Disease
    bioRxiv preprint doi: https://doi.org/10.1101/776666; this version posted September 23, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: An Inter-Species Translation Model Implicates Integrin Signaling in Infliximab-Resistant Colonic Crohn’s Disease Authors: Douglas. K. Brubaker1, Manu. P. Kumar1, Paige, N. Vega2,3, Austin. N. Southard- Smith2,3, Alan. J. Simmons2,3, Elizabeth. A. Scoville4,5, Lori. A. Coburn4,5,6, Keith. T. Wilson4,5,6,7, Ken. S. Lau2,3,5, Douglas. A. Lauffenburger1 Affiliations: 1Department of Biological Engineering, Massachusetts Institute of Technology, MA 02139, USA. 2Epithelial Biology Center, Vanderbilt University School of Medicine, TN 37232, USA. 3Department of Cell and Developmental Biology, Vanderbilt University, TN 37232, USA. 4Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. 5Center for Mucosal Inflammation and Cancer, Vanderbilt University Medical Center, Nashville, TN 37232, USA. 6Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN 37212, USA. 7Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. *To whom correspondence should be addressed: [email protected] One Sentence Summary: Brubaker et al. implicate dysregulated collagen-binding integrin signaling in resistance to anti-TNF therapy in Crohn’s Disease by developing a mouse-proteomic to human-transcriptomic translation model and confirm the associated inter-cellular signaling network using single-cell RNA sequencing. bioRxiv preprint doi: https://doi.org/10.1101/776666; this version posted September 23, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Inflammatory Bowel Disease: Exploring Gut Pathophysiology for Novel Therapeutic Targets
    1 Inflammatory bowel disease: Exploring gut pathophysiology for novel therapeutic targets Vipul Yadav1, Felipe Varum2, Roberto Bravo2, Esther Furrer2, Daniela Bojic2, Abdul W. Basit1 1UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N1AX, UK 2Tillotts Pharma AG, Baslerstrasse 15, CH-4310 Rheinfelden, Switzerland. Corresponding author: Professor Abdul W. Basit UCL School of Pharmacy 29-39 Brunswick Square London, WC1N 1AX, UK Tel.: +44 20 7753 5865; Fax: +44 20 7753 5865. E-mail address: [email protected] Running head: Exploring gut pathophysiology for new targets in IBD Abbreviations: UC=Ulcerative Colitis; CD=Crohn’s Disease; IL=Interleukin; GALT=Gut Associated Lymphoid Tissue; ADA=Adenosine Deaminase; APC=Antigen Presenting Cells; NF-KB=Nuclear Factor Kappa B; IFN= Interferon; DSS=Dextran Sodium Sulfate; STAT=Signal Activator of Transcription; SMAD-7=Mothers against decapentaplegic homolog 7; ECP=Eosinophil Cationic Protein; EPX=Eosinophil Protein X; EPO=Eosinophil Peroxidase; CARD=Caspase Recruitment Domain Family Member; TLRs=Toll-Like Receptors; TNF- α=Tumor Necrosis Factor Alpha; TGF-β1=Transforming growth factor beta 1; iv=Intravenous; sc=Subcutaneous; il=Intralesional; ic=Intracolonic; CAM=Cell Adhesion Molecule; ICAM=Intercellular Adhesion Molecule; MAdCAM=Mucosal Vascular Addressin Cell Adhesion Molecule; LPS=Lipopolysaccharides; FcRn=Neonatal Fc Receptor; NKG2D=Natural killer activating receptor 2D; HSP=Heat Shock Proteins; IP-10=Interferon-γ-Inducible-Protein- 10; MCP=Monocyte Chemoattractant Protein; MIP=Macrophage Inflammatory Protein; MMP=Matrix Metalloproteinases; GLP=Glucagon-like Peptide; FMT=Fecal Microbiota Transplantation; HSC=Haematopoietic Stem Cell; MSC=Mesenchymal Stem Cell; PDLIM2=PDZ and LIM Domain 2; PTEN=Phosphatase and Tensin Homolog 1 2 ABSTRACT Ulcerative colitis (UC) and Crohn’s disease (CD) are the two major phenotypes of inflammatory bowel disease (IBD), which are influenced by a complex interplay of immunological and genetic elements, though the precise aetiology still remains unknown.
    [Show full text]